Guggenheim Begins Coverage on Context Therapeutics (NASDAQ:CNTX)

Key Points

• Guggenheim has initiated coverage on Context Therapeutics (CNTX), assigning a "buy" rating and setting a price target of $5.00, indicating a potential upside of 471.43%.
• Other analysts have given mixed ratings, with HC Wainwright lowering their target to $4.00, while D. Boral Capital maintains a higher target of $9.00.
• Context Therapeutics reported a quarterly loss of ($0.09) earnings per share, which was below the consensus estimate of ($0.06).

Equities research analysts at Guggenheim began coverage on shares of Context Therapeutics (NASDAQ:CNTX - Get Free Report) in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $5.00 price target on the stock. Guggenheim's price target would suggest a potential upside of 402.51% from the company's previous close.

CNTX has been the subject of a number of other reports. Piper Sandler reissued an "overweight" rating and issued a $4.00 target price (down from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. D. Boral Capital reissued a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Thursday, August 7th. Finally, HC Wainwright lowered their price target on shares of Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $5.20.

Context Therapeutics Trading Up 2.8%

Shares of CNTX stock traded up $0.03 during trading hours on Thursday, reaching $1.00. 171,127 shares of the company's stock were exchanged, compared to its average volume of 195,863. The stock's fifty day moving average price is $0.82 and its two-hundred day moving average price is $0.75. The stock has a market cap of $89.25 million, a PE ratio of -2.76 and a beta of 1.90. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $2.59.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). On average, equities analysts expect that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

Institutional investors have recently modified their holdings of the business. Millennium Management LLC increased its stake in Context Therapeutics by 24.2% in the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after buying an additional 34,835 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Context Therapeutics in the fourth quarter valued at about $31,000. Finally, Jane Street Group LLC purchased a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $29,000. Institutional investors own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.